BIGBEAR
PHARMACEUTICAL
Pemigatinib is an oral targeted drug for the treatment of FGFR2 fusion‑positive advanced cholangiocarcinoma.
AuthenticGuaranteeFast DeliveryPrivacy Incyte recently announced that the European Commission (EC) has approved Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) ···【More】
Update: 09 Apr,2026Source: BigbearViews: 88
In April 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Pemazyre (pemigatinib) oral tablets, developed by Incyte, f···【More】
Update: 09 Apr,2026Source: BigbearViews: 86
On August 26, 2022, Incyte announced that the U.S. Food and Drug Administration (FDA) has approved Pemazyre (pemigatinib) for the treatment of adult p···【More】
Update: 08 Apr,2026Source: BigbearViews: 88
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
